Salix Pharma's (SLXP) Balsalazide Sodium Tablets Receive FDA Approval -Bloomberg
Down)
Shares of Salix Pharma (Nasdaq: SLXP) have ticked higher over the last few minutes of trade as Bloomberg is reporting the company's balsalazide sodium tablets have won FDA approval.
The stock last traded at $48.86.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
The stock last traded at $48.86.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Facebook (FB) Could Boost Revs with This Potential Acquisition...
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Celldex (CLDX) volatility up into conference call to announce EMERGE results
Create E-mail Alert Related Categories
FDA, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
